- Home
- KAI vs KNSA Comparison
KAI vs KNSA Comparison
Compare KAI & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KAI | KNSA |
|---|---|---|
| Founded | 1991 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | 366 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.5B |
| IPO Year | 1996 | 2018 |
Fundamental Metrics
Financial Performance| Metric | KAI | KNSA |
|---|---|---|
| Price | $304.52 | $45.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $337.50 | $55.29 |
| AVG Volume (30 Days) | 161.0K | ★ 599.1K |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | ★ 0.42% | N/A |
| EPS Growth | N/A | ★ 225.00 |
| EPS | ★ 8.65 | 0.75 |
| Revenue | ★ $1,052,248,000.00 | $677,564,000.00 |
| Revenue This Year | $13.28 | $38.01 |
| Revenue Next Year | $4.87 | $17.42 |
| P/E Ratio | ★ $37.19 | $61.55 |
| Revenue Growth | N/A | ★ 60.09 |
| 52 Week Low | $244.87 | $18.26 |
| 52 Week High | $369.97 | $49.12 |
Technical Indicators
Market Signals| Indicator | KAI | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 35.33 | 51.17 |
| Support Level | $291.54 | $40.47 |
| Resistance Level | $308.33 | $46.48 |
| Average True Range (ATR) | 14.26 | 2.12 |
| MACD | -4.11 | -0.09 |
| Stochastic Oscillator | 0.82 | 68.45 |
Price Performance
Historical ComparisonAbout KAI Kadant Inc
Kadant Inc. supplies process and engineering equipment for papermaking, recycling, lumber manufacturing, and related industries. The company's three reportable segments are the Flow Control segment which consists of the fluid-handling and doctoring, cleaning, & filtration product lines; the Industrial Processing segment which consists of the wood processing and stock-preparation product lines; and Material handling systems, which provides conveyor-belt equipment for industries such as mining, food processing, and packaging. The company has a geographic presence in the U.S., China, Asia, Germany, Canada, and Others.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.